Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of cumulative low-dose occupational ionizing radiation exposure with hypertension and blood pressure: a cross-sectional study of Chinese medical radiologists.

Journal of hypertension·2026
Same author

The Mediating Role of Inner Strength in the Relationship Between Illness Perception and Self-Management in Older Adults with Advanced Lung Cancer: A Cross-Sectional Study.

Healthcare (Basel, Switzerland)·2026
Same author

Economic evaluation of telemedicine-based integrated management of atrial fibrillation in rural China: a modeling analysis.

NPJ digital medicine·2026
Same author

Effect of a WeChat Intervention Based on the Common-Sense Model on Breast Cancer-Related Lymphedema Preventive Behaviors: Quasi-Experimental Study.

JMIR formative research·2026
Same author

Village Doctor-Led Telemedicine for Rural Patients Aged 75 Years and Older With AF: A Prespecified Secondary Analysis of the MIRACLE-AF Trial.

JAMA network open·2026
Same author

Temporal Characteristics and Management of Prolonged Sinus Pause Following Atrial Fibrillation Termination After Catheter Ablation-A Preliminary Study.

Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc·2026
Same journal

Anticholinergic and central nervous system-active drug burdens and their associations with adverse in-hospital outcomes among older inpatients.

British journal of clinical pharmacology·2026
Same journal

N-acetylcysteine for non-paracetamol-induced acute liver failure in children: A systematic review and meta-analysis.

British journal of clinical pharmacology·2026
Same journal

Anti-seizure medications and DRESS in paediatric patients: A FAERS disproportionality and time-to-onset analysis.

British journal of clinical pharmacology·2026
Same journal

Modelling immune gene expression profiles as pharmacodynamic endpoints of antileishmanial treatment.

British journal of clinical pharmacology·2026
Same journal

The effect of mild and moderate hepatic impairment on the pharmacokinetics, safety and tolerability of balcinrenone.

British journal of clinical pharmacology·2026
Same journal

Relationship between continuous infusion meropenem PK/PD target attainment and C-reactive protein dynamics in onco-haematologic patients with febrile neutropenia.

British journal of clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Pharmacotherapy for obesity.

Mingfang Li1, Bernard M Y Cheung

  • 1Department of Medicine, the University of Hong Kong, Hong Kong.

British Journal of Clinical Pharmacology
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Anti-obesity medications like sibutramine and orlistat aid weight management alongside lifestyle changes. Long-term safety and efficacy studies are crucial for these drugs, especially after rimonabant

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Related Experiment Videos

Last Updated: Jun 17, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

Area of Science:

  • Pharmacology
  • Metabolic Disorders
  • Cardiovascular Health

Background:

  • Obesity is a significant risk factor for hypertension, dyslipidemia, diabetes mellitus, and obstructive sleep apnea.
  • Pharmacotherapy for obesity is recommended for obese patients or overweight individuals with comorbidities, in conjunction with lifestyle modifications.
  • Current long-term approved anti-obesity medications include sibutramine (appetite suppressant) and orlistat (fat absorption inhibitor).

Purpose of the Study:

  • To review the role of pharmacotherapy in obesity management.
  • To discuss the mechanisms, efficacy, and limitations of currently approved anti-obesity agents.
  • To highlight the need for further research into the long-term safety and effectiveness of anti-obesity medications.

Main Methods:

  • Review of existing clinical trial data and regulatory agency announcements regarding anti-obesity medications.
  • Analysis of the pharmacological profiles and side effect profiles of sibutramine, orlistat, and rimonabant.
  • Identification of gaps in knowledge regarding long-term outcomes of anti-obesity pharmacotherapy.

Main Results:

  • Sibutramine and orlistat are the only anti-obesity drugs approved for long-term use.
  • Sibutramine acts centrally to reduce food intake, while orlistat reduces dietary fat absorption but causes gastrointestinal side effects.
  • Rimonabant, an endocannabinoid receptor antagonist, was withdrawn due to psychiatric side effects, underscoring safety concerns.

Conclusions:

  • Anti-obesity pharmacotherapy can be a valuable component of comprehensive weight management strategies.
  • Careful consideration of drug mechanisms, efficacy, and potential adverse effects is essential.
  • Further research is imperative to establish the long-term safety and efficacy profiles of anti-obesity agents to guide clinical practice.